OncoMatch/Clinical Trials/NCT07210775
Topical Imiquimod Treatment of Oral Dysplasia
Is NCT07210775 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Imiquimod (topical use) for oral dysplasia.
Treatment: Imiquimod (topical use) — The goal of this clinical trial is to determine the effectiveness of imiquimod in treating oral dysplasia in adult patients. Imiquimod 5% cream could be a safe and practical treatment for oral epithelial dysplasia (a precancerous change in the mouth). The main questions it aims to answer are: 1. Does imiquimod help to make the lesions smaller and make the abnormal cell changes less severe? 2. How can we make this treatment safer and more feasible? Participants will apply topical imiquimod cream to treat the oral dysplasia and receive two follow-up biopsies after the treatment.
Check if I qualifyEligibility summary
For patients with oral dysplasia.
This summary was generated by AI from the trial's official eligibility criteria and may contain errors. Always confirm with the study team before contacting a site.
US trial sites
- OralCare PreCancer and Pain Clinic · Los Angeles, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify